6,389 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by PSP Research LLC

PSP Research LLC bought a new position in Inhibrx Biosciences, Inc. (NASDAQ:INBX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 6,389 shares of the company’s stock, valued at approximately $505,000.

A number of other hedge funds also recently bought and sold shares of INBX. Strs Ohio bought a new stake in Inhibrx Biosciences in the 1st quarter worth approximately $27,000. Public Employees Retirement System of Ohio bought a new stake in Inhibrx Biosciences in the third quarter valued at approximately $40,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Inhibrx Biosciences by 26.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 707 shares of the company’s stock valued at $56,000 after purchasing an additional 147 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Inhibrx Biosciences by 71.9% in the third quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock valued at $64,000 after purchasing an additional 789 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in Inhibrx Biosciences by 19.2% in the second quarter. Bank of America Corp DE now owns 9,130 shares of the company’s stock valued at $130,000 after purchasing an additional 1,469 shares during the last quarter. Institutional investors own 82.46% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Inhibrx Biosciences in a research report on Thursday, January 22nd. Wall Street Zen upgraded Inhibrx Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Lifesci Capital upgraded Inhibrx Biosciences to a “strong-buy” rating in a research report on Friday, April 24th. Zacks Research upgraded Inhibrx Biosciences to a “hold” rating in a research report on Thursday, April 9th. Finally, Stifel Nicolaus started coverage on Inhibrx Biosciences in a report on Wednesday, April 8th. They set a “buy” rating and a $150.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $150.00.

Inhibrx Biosciences Price Performance

Shares of Inhibrx Biosciences stock opened at $109.51 on Wednesday. The company has a quick ratio of 6.46, a current ratio of 6.46 and a debt-to-equity ratio of 12.58. The company has a market cap of $1.61 billion, a PE ratio of -13.05 and a beta of 3.88. The business has a 50 day moving average of $89.15 and a 200 day moving average of $82.73. Inhibrx Biosciences, Inc. has a 52 week low of $12.24 and a 52 week high of $155.29.

Inhibrx Biosciences (NASDAQ:INBX) last announced its earnings results on Thursday, May 14th. The company reported ($2.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.47). As a group, equities research analysts forecast that Inhibrx Biosciences, Inc. will post -10.15 earnings per share for the current year.

Inhibrx Biosciences Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.